MPP joins ATOM, a new global coalition to increase access to and the use of essential cancer medicines in low and lower middle-income countries
WHO and MPP announce names of 15 manufactures to receive training from mRNA technology transfer hub
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.
"The Medicines Patent Pool was established as a landmark initiative to expand access to treatments for priority diseases. Over the last decade, MPP has become a strong partner in global health, working to facilitate access to HIV and hepatitis C medicines in low- and middle-income countries through voluntary licensing and patent pooling. With its impressive track record, MPP has a critical role to play in making affordable versions of patented essential medicines and technologies available to those who need it the most, including for COVID-19."Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
"The creation fo the Medicines Patent Pool by Unitaid ten years ago enabled the production of generics that treat tens of millions of people around the world. This led to important successes such as an annual treatment for HIV/AIDS for less than USD 70 in Africa, instead of USD 10,000 in Europe. Today, maybe more than ever, we need MPP’s model to help pharmaceutical companies license their rights on a voluntary basis and continue to save lives."Marisol Touraine, Chair of the Executive Board of Unitaid
"As the Medicines Patent Pool celebrates its ten-year anniversary, we are proud to support MPP’s effort to speed up access to essential medicines in low- and middle-income countries. MPP’s voluntary licence mechanism is very much needed, especially in times of the COVID-19 pandemic, as it promotes a collaborative vision of ensuring rapid access of quality-assured affordable essential medicines to people living in low- and middle-income countries while acknowledging the need to fund innovation."Alexander Schulze, Head of the Division Global Programme Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation
MPP in Numbers
patent holders with MPP signed agreements
generic manufactures and product developers have sublicenses from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in March 2022 (data as of 31 December 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
How access to antiretrovirals is building the future
#StartingNow｜High-level event during #WHA75 on the #mRNA Technology Transfer Hub Programme Moderator @follybahAJE welcoming Ministers and country representatives of the 1st panel from #France 🇫🇷 #Canada 🇨🇦 #Brazil 🇧🇷 #Egypt 🇪🇬 https://t.co/DOBiLy33Mj https://t.co/9hfpqoaS59
📢Starting in 45 minutes‼️ Follow our high-level event during #WHA75 on the #mRNA Technology Transfer Hub Programme. ⏰Today, 17h45-18h45 CET 🤝🏽 co-hosted by @dsigovza @francediplo_EN @MedsPatentPool, supported by @WHO Still time to register👉🏽 https://t.co/DOBiLy33Mj https://t.co/t9u1Qx7Gpn
🤩Yesterday we celebrated @UNITAID's 15th anniversary ✅@UNITAID created MPP 1⃣1⃣ years ago which allows pharmaceutical companies to license their rights on a voluntary basis 👉🏽This has enabled the production of generics that treat tens of millions of people around 🌍 https://t.co/NNNJNDBQIx
France ONU Genève 🇫🇷🇪🇺 @FranceONUGeneve
🚨 J-4 avant le webinaire sur la capacité de fabrication de #vaccins grâce à la plateforme de transfert de technologie ARNm organisé par @dsigovza, @MedsPatentPool & @FranceONUGeneve et le soutien de @WHO 📅 23 mai ⏰ 17h45 à 18h45 CET 🔗 Inscription 👉 https://t.co/Z8U43oYkbt https://t.co/CC6mpmZwrU
Esteban Burrone @eburrone
Happy anniversary to @Unitaid! In only 15 years it has had an enormous impact on improving diagnosis and treatment for HIV, hepC and TB. It has been a huge pleasure and honour to work together, as the founder, funder and critical partner of @MedsPatentPool during all these years